Secukinumab falls short in GCA trial

2 minute read


While the study didn’t meet its primary endpoint, signals of steroid-sparing potential keep the biologic in the conversation.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×